Meda is a leading international specialty pharma company with a broad product portfolio reaching more than 80% of the global pharmaceutical market. Sales at the end of 2015 amounted to more than SEK 19,6 billion.
At the end of 2015 Meda had around 4,600 (5,200) employees, 2,690 (2,900) of which worked in sales and marketing. The company’s main focus is sales and marketing and Meda has its own sales organizations in more than 60 countries. Sales and marketing activities are carried out via distributors in countries where Meda has no representation and globally Meda’s products are sold in more than 150 countries. Over the past few years Meda’s presence in growth markets has grown. The marketing organizations in these markets employ about 1,100 people (1,083).
In 2014 Meda acquired the Italian specialty pharma company Rottapharm and after the acquisition, around 60% of Meda’s product sales are in the prescription area (Rx) and around 40% are in non-prescription (Cx and OTC). Meda has a broad product portfolio but there are three key therapy areas – Respiratory, Dermatology and Pain and Inflammation – accounting for around 50% of company sales.
Meda does not conduct any, early-stage pharmaceutical development. New products are secured through acquisitions. Instead, Meda is focused on market-adapted product development in key therapy areas, and sales and marketing.
Meda AB is the parent company and its head office is located in Solna, Sweden. Meda was listed in 1995 at the Stockholm stock market and since 2006 listed under Large Cap on NASDAQ Stockholm in Sweden.
Rx products are prescription based pharmaceuticals prescribed by doctors and therapists for patients.
OTC products are over the counter products sold directly to consumers via pharmacies and retail chains.
Cx are clinically-proven consumer healthcare products recommended by doctors and pharmacists to consumers.